N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-ethyl-6-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-(1-methylpiperidin-4-yl)benzofuran-4-carboxamide

ID: ALA4169762

Chembl Id: CHEMBL4169762

PubChem CID: 145954657

Max Phase: Preclinical

Molecular Formula: C32H44N4O4

Molecular Weight: 548.73

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CCc1c(N(CC)C2CCOCC2)cc2oc(C3CCN(C)CC3)cc2c1C(=O)NCc1c(C)cc(C)[nH]c1=O

Standard InChI:  InChI=1S/C32H44N4O4/c1-6-24-27(36(7-2)23-10-14-39-15-11-23)18-29-25(17-28(40-29)22-8-12-35(5)13-9-22)30(24)32(38)33-19-26-20(3)16-21(4)34-31(26)37/h16-18,22-23H,6-15,19H2,1-5H3,(H,33,38)(H,34,37)

Standard InChI Key:  RNOUJORPHZOBFA-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4169762

    ---

Associated Targets(Human)

EZH1 Tchem EZH1/SUZ12/EED/AEBP2/RBBP4 complex (29 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Pfeiffer (261 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 548.73Molecular Weight (Monoisotopic): 548.3363AlogP: 5.04#Rotatable Bonds: 8
Polar Surface Area: 90.81Molecular Species: BASEHBA: 6HBD: 2
#RO5 Violations: 2HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.64CX Basic pKa: 8.78CX LogP: 3.02CX LogD: 1.62
Aromatic Rings: 3Heavy Atoms: 40QED Weighted: 0.41Np Likeness Score: -0.90

References

1. Lu B, Shen X, Zhang L, Liu D, Zhang C, Cao J, Shen R, Zhang J, Wang D, Wan H, Xu Z, Ho MH, Zhang M, Zhang L, He F, Tao W..  (2018)  Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma.,  (2): [PMID:29456795] [10.1021/acsmedchemlett.7b00437]

Source